Anthracyclines News and Research

RSS
Impact of cancer treatment on cardiovascular function

Impact of cancer treatment on cardiovascular function

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Cell Therapeutics reports cardiac safety results from phase II trial of pixantrone in CHOP-R regimen

Survival improving in patients with HER2 positive metastatic breast cancer

Survival improving in patients with HER2 positive metastatic breast cancer

Survival rate is improving in HER2 positive breast cancer patients

Survival rate is improving in HER2 positive breast cancer patients

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

Abnormality on chromosome 17 helps detect breast cancer tumour's response to anthracyclines

SpePharm Holding acquires global rights to Savene from TopoTarget

SpePharm Holding acquires global rights to Savene from TopoTarget

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

Researchers identify new gene signature that predicts cancer recurrence in certain breast tumors

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

Trabectedin now available for patients with advanced soft tissue sarcoma

Trabectedin now available for patients with advanced soft tissue sarcoma

INS cites FDA-approved Totect antidote for anthracycline extravasations

INS cites FDA-approved Totect antidote for anthracycline extravasations

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Updated results from phase III EXTEND clinical trial of pixantrone released

Updated results from phase III EXTEND clinical trial of pixantrone released

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

CytRx plans Phase 2 clinical trial of its doxorubicin prodrug for advanced gastric cancer

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study

Cytrx initiates tamibarotene and TRISENOX combination dose escalation study